Candel Therapeutics, Inc. announced the launch of an underwritten public offering of $80 million of its common stock and pre-funded warrants to certain investors. The net proceeds from the offering will be used to continue the development of their product candidates, including preparing the submission of a Biologics License Application for CAN-2409 in prostate cancer and for general corporate purposes.
Company Information
Company
Candel Therapeutics
Location
Needham, Massachusetts, United States
About
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer. The company is known for its first-in-class oncolytic viral immunotherapy candidate, CAN-3110, which targets Nestin-positive tumors. They aim to extend cancer treatment options beyond traditional methods and focus on innovative therapeutic approaches. Candel aims to address unmet medical needs in oncology with its experimental medicines.
NeedhamBiotechnologyHealth CareTherapeuticsBiopharma